CytomX Therapeutics (CTMX)
2.98
+0.04 (1.36%)
Upcoming Events
Latest Headlines
Form 8-K CytomX Therapeutics, For: May 29
June 3, 2026 4:15 PM - SEC Filing
CytomX expands Regeneron collaboration, receives $37 million payment
June 3, 2026 8:03 AM - StreetInsider
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
June 3, 2026 8:00 AM - Globe NewsWire
CytomX Therapeutics to Present at Upcoming June Investor Conferences
May 21, 2026 8:00 AM - Globe NewsWire
Wolfe Research Starts CytomX Therapeutics (CTMX) at Outperform
May 19, 2026 5:32 AM - StreetInsider
CytomX hires Mamata Gokhale as regulatory affairs head
May 18, 2026 8:01 AM - StreetInsider
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
May 18, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Seven Fleet Capital Management LP
May 15, 2026 5:12 PM - SEC Filing
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Longitude Capital Partners V, LLC
May 15, 2026 4:50 PM - SEC Filing
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
May 15, 2026 4:43 PM - SEC Filing
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Kynam Capital Management, LP
May 15, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
May 15, 2026 4:00 PM - SEC Filing
CytomX Therapeutics (CTMX) PT Lowered to $11 at H.C. Wainwright
May 11, 2026 6:59 AM - StreetInsider
CytomX Therapeutics (CTMX) Tops Q1 EPS by 2c
May 7, 2026 5:40 PM - StreetInsider
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
May 7, 2026 4:15 PM - Globe NewsWire
Form 8-K CytomX Therapeutics, For: May 07
May 7, 2026 4:15 PM - SEC Filing
Form 10-Q CytomX Therapeutics, For: Mar 31
May 7, 2026 4:07 PM - SEC Filing
Form DEFA14A CytomX Therapeutics,
April 30, 2026 4:26 PM - SEC Filing
Form DEF 14A CytomX Therapeutics, For: Jun 17
April 30, 2026 4:21 PM - SEC Filing
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026 8:00 AM - Globe NewsWire
Form PRE 14A CytomX Therapeutics, For: Jun 17
April 20, 2026 4:16 PM - SEC Filing
Increasing unusual put option volume: CTMX BEKE CAR VIAV BK BB MDLN TVTX EA BCS
April 17, 2026 6:03 AM - StreetInsider
Form SCHEDULE 13G CytomX Therapeutics, Filed by: Point72 Asset Management, L.P.
April 16, 2026 4:10 PM - SEC Filing
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 5:40 PM - SEC Filing
Jefferies on CytomX Therapeutics (CTMX): 'we see good entry point at current value' amid Vareseta-M derisking
March 24, 2026 10:19 AM - StreetInsider
CytomX Therapeutics (CTMX) PT Raised to $12 at Piper Sandler
March 23, 2026 9:29 AM - StreetInsider
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Chu Yu-Waye
March 19, 2026 6:41 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: McCarthy Sean A.
March 19, 2026 6:35 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: BELVIN MARCIA
March 19, 2026 6:26 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Ogden Christopher
March 19, 2026 6:21 PM - SEC Filing
Form 8-K CytomX Therapeutics, For: Mar 17
March 19, 2026 4:06 PM - SEC Filing
CytomX Therapeutics (CTMX) PT Raised to $16 at Barclays
March 19, 2026 3:36 AM - StreetInsider
Form 424B5 CytomX Therapeutics,
March 18, 2026 4:07 PM - SEC Filing
CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here'
March 18, 2026 10:16 AM - StreetInsider
CytomX Therapeutics prices $250 million stock offering at $5.30
March 17, 2026 10:47 PM - StreetInsider
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
March 17, 2026 10:46 PM - Globe NewsWire
CytomX Therapeutics (CTMX) PT Raised to $15 at Guggenheim
March 17, 2026 6:33 AM - StreetInsider
Form 424B5 CytomX Therapeutics,
March 16, 2026 4:38 PM - SEC Filing
CytomX announces $250 million public offering of stock and warrants
March 16, 2026 4:06 PM - StreetInsider
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
March 16, 2026 4:05 PM - Globe NewsWire
CytomX Therapeutics (CTMX) files mixed shelf
March 16, 2026 4:04 PM - StreetInsider
Form S-3ASR CytomX Therapeutics,
March 16, 2026 4:02 PM - SEC Filing
CytomX Therapeutics (CTMX) PT Raised to $17 at H.C. Wainwright
March 16, 2026 12:02 PM - StreetInsider
JPMorgan Upgrades CytomX Therapeutics (CTMX) to Overweight
March 16, 2026 11:57 AM - StreetInsider
CytomX Therapeutics (CTMX) PT Raised to $12 at Oppenheimer
March 16, 2026 9:30 AM - StreetInsider
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
March 16, 2026 7:05 AM - Globe NewsWire
Form 8-K CytomX Therapeutics, For: Mar 16
March 16, 2026 7:04 AM - SEC Filing
Form 10-K CytomX Therapeutics, For: Dec 31
March 16, 2026 7:03 AM - SEC Filing
CytomX reports positive phase 1 data for colorectal cancer treatment
March 16, 2026 7:01 AM - StreetInsider
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
March 16, 2026 7:00 AM - Globe NewsWire
Full Article List
